Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Astex Pharmaceuticals Issues Open Letter to Stockholders Regarding Otsuka Transaction

By Pharmaceutical Processing | October 3, 2013

The Board of Directors of Astex Pharmaceuticals, Inc. has issued a letter to Astex stockholders addressing recent mischaracterizations of the pending acquisition of the Company by Otsuka Pharmaceutical Co., Ltd. The full text of the letter follows:

October 2, 2013

Dear Fellow Stockholder,

A number of misstatements and falsehoods have recently been circulated regarding the current tender offer from Otsuka to acquire Astex. Our public statements and SEC filings have been consistent as to the thoroughness of the sale process and the resulting merger agreement.
The purpose of this letter is to set the record straight.

To understand why we, the Astex Board of Directors, have unanimously determined that the Otsuka transaction is in the best interest of Astex stockholders, consider the following:

  —  The Otsuka transaction is the culmination of a comprehensive process to
      maximize value for Astex stockholders. As part of that process, 33
      pharmaceutical companies worldwide were contacted to gauge their
      interest in exploring a potential strategic transaction with Astex. All
      companies contacted were given an equal opportunity to participate in
      the process. Of the 33 companies contacted, only five, including Otsuka,
      executed non-disclosure agreements that contained customary terms,
      enabling them to conduct detailed due diligence on confidential
      information related to, amongst other things, the Company’s pipeline of
      products, financial condition and capital structure. Otsuka was the only
      company to submit a final proposal to acquire the Company.

  —  Since the agreement with Otsuka was announced on September 5, 2013, no
      third parties have approached Astex with an interest to acquire the
      Company.

  —  Astex’s Board carefully considered not only the new, preliminary and
      interim results of the SGI−110 trials but also the potential
      future economic risks and benefits of its products in development. On
      August 28, 2013, the Company issued a press release announcing
      preliminary top−line results of the SGI−110 AML Phase 2
      clinical trial, prior to considering final bids for the acquisition of
      the Company. Otsuka was provided with access to these results as part of
      the auction process. In assessing the valuation of Astex, the Board took
      into account not only the preliminary results that were announced on
      August 28, 2013, but also the potential future economic risks and
      benefits of SGI-110 and the other pipeline products, as outlined in
      Astex’s Schedule 14D-9.

  —  Astex negotiated with Otsuka to achieve a higher offer. Otsuka
      originally indicated that it would offer $7.75 per share for each
      outstanding share of Astex. The Astex Board, as part of its thorough
      process, rejected the initial offer, and based on, among other things,
      the preliminary SGI-110 clinical trial results, negotiated to a final
      offer of $8.50 in cash per share.

  —  Astex believes Otsuka’s cash offer provides stockholders with immediate
      and significant value. Otsuka’s offer of $8.50 per share in cash
      represents 52%, 89%, 84% and 181% premiums to the closing trading prices
      for the 30 days, 60 days, 90 days and one year prior, respectively, to
      September 3, 2013, the last trading day before the Board approved the
      Otsuka transaction.

  —  The proposed transaction with Otsuka eliminates the need for issuance of
      significant dilutive equity capital in the future to fund development
      programs. In order to fund existing development programs, such as
      SGI-110, as well as other discovery and development programs, Astex will
      need extensive financing.  If the Company remains independent, this will
      require issuance of significant amounts of equity capital that would be
      dilutive to existing stockholders. The transaction with Otsuka removes
      the need for the Company to issue dilutive equity capital and will
      immediately deliver cash to stockholders, at a significant premium, with
      no value risk and no future dilution risk.

  —  Otsuka has not discussed specific employment terms or roles with Astex
      management. Although Otsuka indicated that it expects there to be
      continuity in management following the consummation of the acquisition,
      neither Otsuka nor Astex has conditioned the transaction on employee
      retention nor has Otsuka or anyone in Astex management discussed
      concrete employment arrangements.

  —  Astex proactively released the only remaining standstill provisions with
      a third party. This third party, referred to as “Company B” in Astex’s
      Schedule 14D-9, had submitted a preliminary indication of interest to
      acquire Astex for $6.00 to $7.00 per share, but terminated its pursuit
      of an acquisition because it was unwilling to support an offer price in
      the range it initially indicated. Although there can be no assurances,
      we do not anticipate that Company B will renew its interest in acquiring
      Astex, even after the release of the standstill provisions.

  —  If more than 50% of stockholders do not tender their shares by the
      scheduled expiration date of October 10, 2013, it would impose
      substantial additional risk that Otsuka could ultimately walk away from
      the transaction.  If Otsuka were to do so, Astex shares could retreat to
      pre-tender offer values substantially below $8.50 per share. The Astex
      Board believes that it is in the best interests of stockholders to
      tender into the offer prior to its scheduled expiration so as not to
      jeopardize Otsuka’s current offer price of $8.50 per share.

We thoroughly examined the Otsuka offer, firmly believe that it is in the best interests of Astex stockholders, and unanimously recommend that stockholders tender their shares pursuant to the tender offer.

If you have any questions or need assistance tendering your shares, please contact Innisfree M&A by calling toll-free at (877) 825-8971 or by calling collect at (212) 750-5833.

Thank you for your continued support.

Sincerely,

Astex Board of Directors

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE